Atomwise is an artificial intelligence company focused on using deep learning for structure-based drug design and discovery. The company applies convolutional neural networks to predict binding affinity between small molecules and protein targets, enabling faster and more efficient virtual screening for pharmaceutical and biotech partners.
Think of NVIDIA BioNeMo as a set of very smart chemistry and biology "co-pilots" that can read and write molecules and proteins the way ChatGPT reads and writes text. Instead of scientists manually trying out millions of possibilities in the lab, BioNeMo helps them design and screen promising drug candidates on a computer first, massively narrowing the search space.
Think of this like a super-smart safety inspector for new medicines. Instead of testing every drug only in animals or long, expensive lab studies, a machine learning system studies lots of past data about how drugs affect human cells and then predicts which new drug candidates are likely to be toxic to peopleâbefore they ever reach clinical trials.
Think of these biotechs as âAI-powered discovery enginesâ for new medicines: instead of scientists testing millions of molecules one by one in a lab, they use advanced algorithms to search, simulate, and shortlist the most promising drug candidates before expensive experiments begin.
Think of this as putting a super-fast robot scientist and a tireless data analyst together in your lab. The robot runs thousands of chemistry and biology experiments automatically, while the AI watches the data, spots patterns humans would miss, and suggests the next best experiments to run to find promising new drugs much sooner.
Think of AI in drug discovery as a super-fast, never-tired lab assistant that can read millions of scientific papers, simulate how molecules behave in the body, and shortlist the most promising drug candidates long before a human team could finish the first pass.